ForDoz Pharma has entered into an agreement with LipoMedix for manufacturing its lead compound, pegylated liposomal Promitil® (PL-MLP) for a Phase 2 clinical study.
Promitil's unique liposomal formulation is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemoradiotherapy. In studies, it has been shown to be active against a broad variety of cancer types in animal models, including colorectal, gastric, pancreatic and multi-drug resistant tumors.
"Our mission is to ultimately aid in the delivery of innovative medicines that will help people live longer and better lives," said James He, founder and CEO of ForDoz. "We are proud to partner with LipoMedix to help them develop and manufacture Promitil here in the United States."
"We continue to move full-steam ahead, knowing that the patients we can help with Promitil have been long awaiting a low-toxicity and effective treatment option," said Dr. Alberto Gabizon, President and Chief Scientific Officer of LipoMedix. "We are thinking long term when selecting our partnerships and look forward to partnering with ForDoz on the next phase of our journey to bring Promitil to those who need it most."
Sanjeev Luther, Executive Chairman of the Board of LipoMedix, said, "ForDoz has a proven track record in manufacturing and in successful commercialization. Selecting the right partner for each step of the journey is critical to the strategic process of developing a drug. By leveraging ForDoz's drug delivery technology and experience, LipoMedix will be able to effectively troubleshoot the many challenges of product development and manufacturing."
